IL6 and neoplasm: It has been reported that activation of the Wnt/β-catenin pathway and IL-6/STAT3 signaling by LRP5 could promote neoplasm cells to acquire chemoresistance and the cancer stem cell phenotype, which should be considered when establishing chemotherapeutic approaches against ameloblastomas [40].